Equitable Trust Co. Lowers Holdings in Encompass Health Co. (NYSE:EHC)

Equitable Trust Co. decreased its stake in Encompass Health Co. (NYSE:EHC) by 9.3% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,829 shares of the company’s stock after selling 600 shares during the quarter. Equitable Trust Co.’s holdings in Encompass Health were worth $500,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the stock. Trillium Asset Management LLC purchased a new position in Encompass Health during the first quarter worth approximately $4,432,000. TD Asset Management Inc boosted its position in Encompass Health by 16.0% during the first quarter. TD Asset Management Inc now owns 2,283,674 shares of the company’s stock worth $188,586,000 after purchasing an additional 314,488 shares in the last quarter. Harbor Capital Advisors Inc. boosted its position in Encompass Health by 275.7% during the second quarter. Harbor Capital Advisors Inc. now owns 35,799 shares of the company’s stock worth $3,071,000 after purchasing an additional 26,270 shares in the last quarter. TimesSquare Capital Management LLC boosted its position in Encompass Health by 18.1% during the fourth quarter. TimesSquare Capital Management LLC now owns 1,150,866 shares of the company’s stock worth $76,786,000 after purchasing an additional 175,975 shares in the last quarter. Finally, Epoch Investment Partners Inc. boosted its position in Encompass Health by 102.9% during the fourth quarter. Epoch Investment Partners Inc. now owns 1,399,341 shares of the company’s stock worth $93,364,000 after purchasing an additional 709,593 shares in the last quarter. Hedge funds and other institutional investors own 97.25% of the company’s stock.

Encompass Health Trading Up 1.6 %

Shares of Encompass Health stock opened at $93.05 on Monday. The firm has a market capitalization of $9.36 billion, a price-to-earnings ratio of 25.15, a PEG ratio of 1.42 and a beta of 0.89. Encompass Health Co. has a fifty-two week low of $57.55 and a fifty-two week high of $94.38. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.35 and a current ratio of 1.35. The stock has a 50 day moving average of $87.89 and a 200 day moving average of $83.49.

Encompass Health (NYSE:EHC) last released its quarterly earnings results on Monday, August 5th. The company reported $1.11 EPS for the quarter, topping the consensus estimate of $1.01 by $0.10. The business had revenue of $1.30 billion during the quarter, compared to analyst estimates of $1.30 billion. Encompass Health had a return on equity of 17.83% and a net margin of 7.88%. The company’s quarterly revenue was up 9.6% on a year-over-year basis. During the same period last year, the business posted $0.95 earnings per share. As a group, research analysts predict that Encompass Health Co. will post 4.17 earnings per share for the current year.

Encompass Health Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, October 15th. Investors of record on Tuesday, October 1st will be issued a $0.17 dividend. The ex-dividend date of this dividend is Tuesday, October 1st. This is a positive change from Encompass Health’s previous quarterly dividend of $0.15. This represents a $0.68 dividend on an annualized basis and a yield of 0.73%. Encompass Health’s dividend payout ratio (DPR) is 16.22%.

Insider Buying and Selling at Encompass Health

In other Encompass Health news, CFO Douglas E. Coltharp sold 12,260 shares of the firm’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $86.34, for a total value of $1,058,528.40. Following the sale, the chief financial officer now directly owns 136,227 shares in the company, valued at $11,761,839.18. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 2.10% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of brokerages have issued reports on EHC. Barclays lowered their price target on Encompass Health from $113.00 to $109.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 6th. Stephens reissued an “overweight” rating and set a $105.00 target price on shares of Encompass Health in a report on Tuesday, August 6th. Royal Bank of Canada increased their target price on Encompass Health from $83.00 to $95.00 and gave the company an “outperform” rating in a report on Wednesday, May 22nd. Leerink Partners began coverage on Encompass Health in a report on Wednesday, July 10th. They set an “outperform” rating and a $100.00 target price for the company. Finally, Truist Financial increased their target price on Encompass Health from $100.00 to $104.00 and gave the company a “buy” rating in a report on Thursday, August 15th. Nine analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $100.38.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.